Pharmaceutical companies Develop new corona drug and confirm effectiveness of existing drugs Hurry April 23, 6:25
k10012401331_202004230622_202004230624.mp4
A major Japanese pharmaceutical company is developing a therapeutic drug for the new coronavirus, and is rushing into clinical trials to confirm the efficacy of existing drugs.
Of these, Takeda Pharmaceutical Co., Ltd. is embarking on the development of a therapeutic drug that uses antibodies contained in the blood of patients who have completely recovered from a new coronavirus infection.
In development, we are collaborating with five pharmaceutical companies in the United States and Europe to collect blood from patients and manufacture medicines. By this summer, we will conduct clinical trials of new drugs in Japan and the United States. I am aiming for.
Meanwhile, Chugai is diverting "Actemra," which is used as a therapeutic drug for rheumatoid arthritis, and is preparing clinical trials to confirm its effect on patients with severe pneumonia infected with the new coronavirus.
"Actemra" is a drug that suppresses the immune system from running out of control due to excessive production of a substance called "interleukin 6" that enhances immune function. I am trying to confirm whether it will improve the symptoms.
In addition, clinical trials for Avigan, a new influenza drug developed by a subsidiary of Fujifilm, have already begun this month aiming for national approval.
Pharmaceutical companies around the world, such as the United States and China, are also rushing to develop, and it will be noted whether Japanese pharmaceutical companies can put therapeutic drugs into practical use as quickly as possible.